Renibus Therapeutics Strengthens IP Position with Additional US Patent
13. April 2022 08:00 ET
|
Rénibus Therapeutics Inc.
SOUTHLAKE, Texas, April 13, 2022 (GLOBE NEWSWIRE) -- Renibus Therapeutics® (“Renibus”), a clinical-stage biotech company focusing on the prevention and treatment of cardio-renal diseases, today...
Renibus Therapeutics Announces Presentations at the American Society of Nephrology Kidney Week 2021
28. Oktober 2021 09:00 ET
|
Rénibus Therapeutics Inc.
DALLAS, Texas, Oct. 28, 2021 (GLOBE NEWSWIRE) -- Renibus Therapeutics, Inc., a clinical-stage biotechnology company, announced today that it will present abstracts at the American Society of...
Renibus Therapeutics Initiates Phase 2 Study of RBT-1 for Prevention of Acute Kidney Injury
11. März 2021 09:00 ET
|
Rénibus Therapeutics Inc.
- Renibus plans to enroll 126 subjects at up to 20 sites across the United States, Canada, Australia, and New Zealand DALLAS, Texas, March 11, 2021 (GLOBE NEWSWIRE) -- Renibus Therapeutics®...
Rénibus Therapeutics to Present Phase 1b Data on RBT-1 at Acute Kidney Injury & Continuous Renal Replacement Therapy 2021 Conference
25. Februar 2021 09:00 ET
|
Rénibus Therapeutics Inc.
DALLAS, Texas, Feb. 25, 2021 (GLOBE NEWSWIRE) -- Rénibus Therapeutics, Inc., a clinical-stage biotech company focusing on the prevention, treatment, and diagnostic testing of kidney disease,...
Renibus Therapeutics Announces Publication of Positive Results of RBT-3 Experimental Preclinical Studies in Scientific Journal Nephrology Dialysis Transplant
16. Februar 2021 09:00 ET
|
Rénibus Therapeutics Inc.
-With no currently approved therapies for the prevention or treatment of platinum-induced toxicity, RBT-3 has the potential to fill a critical unmet medical need Dallas, Texas, Feb. 16, 2021 ...
Renibus Therapeutics Announces Presentations at the American Society of Nephrology Kidney Week 2020
19. Oktober 2020 09:00 ET
|
Rénibus Therapeutics Inc.
DALLAS, Texas, Oct. 19, 2020 (GLOBE NEWSWIRE) -- Renibus Therapeutics, Inc., a clinical-stage biotechnology company, announced today that it will present five abstracts at the American Society of...
Renibus Therapeutics’ COVID-19 Treatment, RBT-9, Shows Antiviral Activity Against SARS-CoV-2 In Vitro
07. Oktober 2020 09:00 ET
|
Rénibus Therapeutics Inc.
DALLAS, Texas, Oct. 07, 2020 (GLOBE NEWSWIRE) -- Renibus Therapeutics, Inc., a clinical-stage biotechnology company, announced today that its investigational treatment for COVID-19, RBT-9, has...
Renibus Therapeutics Receives FDA Fast Track Designation for RBT-9 Treatment in COVID-19
23. Juni 2020 09:00 ET
|
Rénibus Therapeutics Inc.
DALLAS, Texas, June 23, 2020 (GLOBE NEWSWIRE) -- Renibus Therapeutics, Inc., a clinical-stage biotechnology company, announced today that it has been granted Fast Track designation by the FDA for...
Renibus Therapeutics Announces Publication of a Novel Stress Test for Assessing Antioxidant Defenses in Chronic Kidney Disease
16. Juni 2020 09:00 ET
|
Rénibus Therapeutics Inc.
DALLAS, Texas, June 16, 2020 (GLOBE NEWSWIRE) -- Renibus Therapeutics, Inc., a clinical stage biotechnology company developing novel therapies for prevention and treatment of kidney diseases, today...
Renibus Therapeutics Announces Abstract Presentation at the 2020 European Renal Association – European Dialysis and Transplant Association (ERA-EDTA) Annual Congress
09. Juni 2020 09:00 ET
|
Rénibus Therapeutics Inc.
Dallas, June 09, 2020 (GLOBE NEWSWIRE) -- Renibus Therapeutics, Inc, a clinical-stage biotechnology company, is pleased to announce that data highlighting the translation of the mechanism of action...